Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $65.00 price objective on the stock. JSPR has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares […]
More Stories
Social Security Cost-of-Living Adjustment Estimate Raised to 2.7 Percent for 2026
By Tom Ozimek The Social Security cost-of-living adjustment (COLA) for 2026 is projected to be 2.7 percent, according to an...
Trump Heads to Alaska for Pivotal Summit With Putin on Ukraine War
By Emel Akan ANCHORAGE, Alaska—U.S. President Donald Trump departed Washington early on Aug. 15 for Alaska, where he will hold...
Citigroup Inc. Has $11.96 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)
Citigroup Inc. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 13.5% in the 1st quarter,...
Citigroup Inc. Reduces Holdings in Nutanix (NASDAQ:NTNX)
Citigroup Inc. lowered its position in shares of Nutanix (NASDAQ:NTNX – Free Report) by 4.4% during the first quarter, according...
Citigroup Inc. Has $12.47 Million Position in Enovis Corporation (NYSE:ENOV)
Citigroup Inc. lessened its holdings in shares of Enovis Corporation (NYSE:ENOV – Free Report) by 92.5% in the first quarter,...
Citigroup Inc. Grows Stake in Silvercorp Metals Inc. (NYSEAMERICAN:SVM)
Citigroup Inc. increased its stake in Silvercorp Metals Inc. (NYSEAMERICAN:SVM – Free Report) by 8,416.5% in the 1st quarter, HoldingsChannel...